|Stock:||Response Genetics, Inc.|
|Industry:||Medical Laboratories & Research|
|Response Genetics, Inc. is a life sciences company engaged in the research and development of clinical diagnostic tests for cancer. The Company generates revenues primarily from sales of its ResponseDX diagnostic tests. The Company focuses on commercialization of its ResponseDX tests; developing additional diagnostic tests for assessing the risk of cancer recurrence, prediction of chemotherapy response and tumor classification in cancer patients, and expanding its testing services business by pursuing new technologies through collaborations and in-licensing to expand its business. It offers its ResponseDX test services nationwide. The Company offers tests for non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and gastric and gastroesophageal (GE), and melanoma cancer patients’ tumor tissue specimens through its ResponseDX: Lung, ResponseDX: Colon and ResponseDX: Gastric test suites and ResponseDX: Melanoma.|
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.